SpyGlass Pharma (SGP) CEO Patrick Mooney reports initial share and option holdings
Rhea-AI Filing Summary
SpyGlass Pharma, Inc. director and Chief Executive Officer Patrick H. Mooney filed an initial ownership report, showing his beneficial holdings in the company. He directly owns 183,153 shares of common stock and holds several stock options to acquire additional common shares at exercise prices ranging from $0.35 to $7.11, with expiration dates extending to 2035. The options generally vest over four years, with 25% vesting after one year from each grant’s vesting commencement date and the remainder vesting monthly, contingent on his continued service to the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Mooney Patrick H.
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 907,626 shares (Direct);
Common Stock — 183,153 shares (Direct)
Footnotes (6)
- F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 2, 2021.
- F2. Of the 1,696,694 shares subject to the option that were originally granted prior to a 5.7329 to 1 reverse stock split, 1,050,000 shares were exercised pre-reverse stock split and prior to the Reporting Person becoming a Section 16 executive officer and director.
- F3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 6, 2023.
- F4. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean December 13, 2024.
- F5. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 20, 2025.
- F6. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 30, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does SpyGlass Pharma (SGP) disclose in Patrick Mooney’s Form 3?
SpyGlass Pharma reports Patrick H. Mooney’s initial beneficial ownership as director and CEO. He directly holds 183,153 common shares and several stock option grants with various exercise prices and expirations, outlining his equity stake and incentive alignment with the company’s long-term performance.
What stock options in SpyGlass Pharma (SGP) does Patrick Mooney hold?
Patrick H. Mooney holds multiple stock options to buy SpyGlass Pharma common shares, including 112,803 shares at $0.35 and 329,784 shares at $7.11. These options have expiration dates between July 2021 grant-related schedules and July 23, 2035, reflecting long-term incentive awards.
How do Patrick Mooney’s SpyGlass Pharma (SGP) options vest?
Each option grant generally vests 25% on the one-year anniversary of its vesting commencement date, then 1/36 of the remaining shares monthly. Vesting continues only while Mooney remains a “Service Provider” under SpyGlass Pharma’s Amended and Restated 2019 Equity Incentive Plan.
What is noted about the SpyGlass Pharma (SGP) reverse stock split in Mooney’s Form 3?
The filing explains one option originally covered 1,696,694 shares before a 5.7329-to-1 reverse stock split. Of those, 1,050,000 shares were exercised before the reverse split and before Patrick Mooney became a Section 16 executive officer and director at SpyGlass Pharma.
What role does Patrick H. Mooney hold at SpyGlass Pharma (SGP) in this Form 3?
Patrick H. Mooney is identified as both a director and the Chief Executive Officer of SpyGlass Pharma. The Form 3 details his status as a reporting person under Section 16 and outlines his direct common stock holdings and stock option positions in the company.